Now available. Read our 2025 Impact Report
Español de México
1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT Our speaker is Megan McNiff, a research associate from the John Walton Muscular Dystrophy Research Centre, […]
Researchers Identify a New Compound that Inhibits the Activity of DUX4 By Alec DeSimone, PhD University of Massachusetts Medical School Led by a team at the University of Minnesota, Minneapolis, […]
En esta entrevista, el Dr. Jeffery Statland, del Centro Médico de la Universidad de Kansas, explica cómo la financiación de la Sociedad FSH impulsó la creación de la Red de Investigación de Ensayos Clínicos (CTRN) de siete centros, que […]
Written by Jim Albert Eldersburg, Maryland A cancer drug has been shown to potentially rescue some of the damaging effects of DUX4, the gene implicated in FSH muscular dystrophy. […]
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain […]
English English 
العربية
Español de México
Français du Canada
简体中文
